Where is the company located?

The company is located at 9 Yugang Road, Zhengzhou Airport Economic Comprehensive Experimental Zone, Zhengzhou.

What is the main business type of the supplier?

The supplier is a Manufacturer/Factory and Trading Company established in 2004.

Veterinary API Albendazole

Name: Veterinary API Albendazole
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1949235342

Henan, ChinaHenan Muxiang Biological Co., Ltd.

Negotiable

100 kg

Sample price:US$3.00/kg.Request sample

Product profile

Customization

Available

Varieties

Growth Promoting Medicine

Component

Chemical Synthetic Drugs

Model NO.

RAW MATERIALS

Type

The First Class

Pharmacodynamic Influential Factors

Incompatibility

Storage Method

Light Proof

Transport Package

25kg/Bag

Specification

25kg/bag

Origin

Zhengzhou, Henan Province

HS Code

3004909099

Production Capacity

30000 Tons /Year

Key features

Broad-Spectrum Efficacy: Highly active against nematodes, schistosomes, tapeworms, and cysticercosis with strong insecticidal effect.

High Clinical Success Rate: 100% negative conversion rate for hookworm and 100% effective rate for treating trichinosis.

OEM/ODM Support: OEM and ODM services are available for customized product requirements.

Established Manufacturer: Factory established in 2004 with 360 employees and 20 R&D engineers.

Global Market Reach: Main markets include North America, Europe, Southeast Asia, Africa, and Australia.

Flexible Payment Terms: Supports LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Consistent Lead Time: Average lead time is one month for both peak and off-season periods.

Certified Quality: Products come with relevant certifications ensuring safety and efficacy.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤18h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.